Fourteen patients with advanced adenocarcinoma of the lung were treated with a combination chemotherapy of mitomycin C, adriamycin and cisplatin (MAP). The overall response rate was 43% with 6 partial responses. The median duration of response was 5.5 months. The median survival for responders was 17 months, versus 9 months for non-responders. Toxicity included nausea and/or vomiting, alopecia, myelosuppression and renal toxicity. The serial measurement of renal tubular function was found to be useful in detecting renal damage caused by cisplatin containing chemotherapy.